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ABSTRACT 
Stability studies of pharmaceutical products ensuring the maintenance of product quality, safety and efficacy throughout the shelf 
life are considered as pre-requisite for the acceptance and approval of any pharmaceutical product. Stability of a pharmaceutical 
product may be defined as the capability of a particular formulation in a specific container/closure system to remain within its 
physical, chemical, microbiological, toxicological, protective and informational specifications. Stability studies are required to be 
conducted in a planned way following the guidelines issued by ICH, who and or other agencies. Importance of various methods 
followed for stability testing of pharmaceutical products, guidelines issued for stability testing and other aspects related to stability 
of pharmaceutical products have been included in the present review 
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INTRODUCTION 
Stability testing of pharmaceutical products is a complex 
set of procedures involving considerable cost, time 
consumption and scientific expertise in order to build in 
quality, efficacy and safety in a drug formulation
1
. 
Scientific and commercial success of a pharmaceutical 
product can only be ensured with the understanding of 
the drug development process and the myriad tasks and 
milestones that are vital to a comprehensive 
development plan. The most important steps during the 
developmental stages include pharmaceutical analysis 
and stability studies that are required to determine and 
assure the identity, potency and purity of ingredients, as 
well as those of the formulated products
2
. Stability of a 
pharmaceutical product may be defined as the capability 
of a particular formulation in a specific container/closure 
system to remain within its physical, chemical, 
microbiological, toxicological, protective and 
informational specifications
3, 4
. In other words, it is the 
extent to which a product retains, within the specified 
limits, throughout its period of storage and use, the same 
properties and characteristics possessed at the time of its 
packaging. Stability testing thus evaluates the effect of 
environmental factors on the quality of the a drug 
substance or a formulated product which is utilized for 
prediction of its shelf life, determine proper storage 
conditions and suggest labelling instructions. Moreover, 
the data generated during the stability testing is an 
important requirement for regulatory approval of any 
drug or formulation
2
. 
SIGNIFICANCE OF STABILITY TESTING  
The primary reason for stability testing is the concern for 
the well-being of the patient suffering from the disease 
for which the products is designed. Apart from 
degradation of the unstable product into toxic 
decomposition products, loss of activity up to a level of 
85% of that claimed on the label may lead to failure of 
the therapy resulting in death e.g. nitroglycerine tablets 
for angina and cardiac arrest. Because of this concern, it 
has become a legal requirement to provide data for 
certain types of stability tests for the regulatory agencies 
before approval of a new product. Second important 
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concern is to protect the reputation of the manufacturer 
by assuring that the product will retain fitness for use 
with respect to all functionally relevant attributes for as 
long as they are on the market. Other benefits of stability 
studies at the developmental stage or of the marketed 
products are to provide a database that may be of value 
in selection of adequate formulations, excipients and 
container closure systems for development of a new 
product, to determine shelf life and storage conditions 
for development of a new product, preparation of 
registration dossier, to substantiate the claimed shelf life 
for the registration dossier and to verify that no changes 
have been introduced in the formulation or 
manufacturing process that can adversely affect the 
stability of the product
2, 5
. 
STABILITY TESTING METHOD 
Stability testing is a routine procedure performed on 
drug substances and products and is employed at various 
stages of the product development. In early stages, 
accelerated stability testing (at relatively high 
temperatures and/or humidity) is used in order to 
determine the type of degradation products which may 
be found after long-term storage. Testing under less 
rigorous conditions i.e. those recommended for long-
term shelf storage, at slightly elevated temperatures is 
used to determine a product’s shelf life and expiration 
dates. Depending upon the aim and steps followed, 
stability testing procedures have been categorized into 
the following four types:
 
1. Real Time stability testing 
2. Accelerated stability testing 
3. Retained sample stability testing 
4. Cyclic temperature  stress  testing 
Real-time stability testing: 
Real-time stability testing is normally performed for 
longer duration of the test period in order to allow 
significant product degradation under recommended 
storage conditions. The period of the test depends upon 
the stability of the product which should be long enough 
to indicate clearly that no measurable degradation occurs 
and must permit one to distinguish degradation from 
inter-assay variation. During the testing, data is collected 
at an appropriate frequency such that a trend analysis is 
able to distinguish instability from day-to-day 
ambiguity.  
Stability of the reference material also includes the 
stability of reagents as well as consistency of the 
performance of the instrument to be used throughout the 
period of stability testing. However, system performance 
and control for drift and discontinuity resulting from 
changes in both reagents and instrumentation must be 
monitored
6
.
 
Figure 1: Drug product stability testing system. 
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Accelerated stability testing: 
In accelerated stability testing, a product is stressed at 
several high (warmer than ambient) temperatures and 
the amount of heat input required to cause product 
failure is determined. This is done to subject the product 
to a condition that accelerates degradation. This 
information is then projected to predict shelf life or used 
to compare the relative stability of alternative 
formulations. This usually provides an early indication 
of the product shelf life and thus shortening the 
development schedule. In addition to temperature, stress 
conditions applied during accelerated stability testing 
are moisture, light, agitation, gravity, pH and package
3
. 
In accelerated stability testing the samples are subjected 
to stress, refrigerated after stressing, and then assayed 
simultaneously. Because the duration of the analysis is 
short, the likelihood of instability in the measurement 
system is reduced in comparison to the real-time 
stability testing. Further, in accelerated stability testing, 
comparison of the unstressed product with stressed 
material is made within the same assay and the stressed 
sample recovery is expressed as percent of unstressed 
sample recovery. For statistical reasons, the treatment in 
accelerated stability projections is recommended to be 
conducted at four different stress temperatures. 
However, for thermolabile and proteinaceous 
components, relatively accurate stability projections are 
obtained when denaturing stress temperatures are 
avoided
6
. 
Retained sample stability testing: 
This is a usual practice for every marketed product for 
which stability data are required. In this study, stability 
samples, for retained storage for at least one batch a year 
are selected. If the number of batches marketed exceeds 
50, stability samples from two batches are 
recommended to be taken. At the time of first 
introduction of the product in the market, the stability 
samples of every batch may be taken, which may be 
decreased to only 2% to 5% of marketed batches at a 
later stage. In this study, the stability samples are tested 
at predetermined intervals i.e. if a product has shelf life 
of 5 years, it is conventional to test samples at 3, 6, 9, 
12, 18, 24, 36, 48, and 60 months. This conventional 
method of obtaining stability data on retained storage 
samples is known as constant interval method
3, 5
.  
Cyclic temperature stress testing: 
This is not a routine testing method for marketed 
products. In this method, cyclic temperature stress tests 
are designed on knowledge of the product so as to 
mimic likely conditions in market place storage. The 
period of cycle mostly considered is 24 hours since the 
diurnal rhythm on earth is 24 hour, which the marketed 
pharmaceuticals are most likely to experience during 
storage. The minimum and maximum temperatures for 
the cyclic stress testing is recommended to be selected 
on a product by-product basis and considering factors 
like recommended storage temperatures for the product 
and specific chemical and physical degradation 
properties of the products. It is also recommended that 
the test should normally have 20 cycles
3, 5
. 
 
 
Figure 2: Stability during various stages of drug development. 
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GUIDELINE FOR STABILITY TESTING 
These guidelines include basic issues related to stability, 
the stability data requirements for application dossier 
and the steps for their execution. Such guidelines were 
initially issued in 1980s. These were later harmonized 
(made uniform) in the International Conference on 
Harmonization (ICH) in order to overcome the bottle 
neck to market and register the products in other 
countries. The ICH was a consortium formed with inputs 
from both regulatory and industry from European 
commission, Japan and USA. The World Health 
Organization (WHO), in 1996, modified the guidelines 
because the ICH guidelines did not address the extreme 
climatic conditions found in many countries and it only 
covered new drug substances and products and not the 
already established products that were in circulation in 
the WHO umbrella countries. In June 1997, US FDA 
also issued a guidance document entitled ‘Expiration 
dating of solid oral dosage form containing Iron. WHO, 
in 2004, also released guidelines for stability studies in 
global environment
7
 (WHO, 2004). ICH guidelines were 
also extended later for veterinary products. A technical 
monograph on stability testing of drug substances and 
products existing in India has also been released by India 
Drug Manufacturers Association
2
. Further, different test 
condition and requirements have been given in the 
guidance documents for active pharmaceutical 
ingredients, drug products or formulations and 
excipients. The codes and titles for stability studies 
covered under ICH guidance have been outlined in the 
table.  
 
Table 1: Codes and titles used in ICH Guidelines 
 
 Q1 A (R2): Stability testing of new drug substances 
and products: 
The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product 
varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, 
and light, and to establish a re-test period for the drug 
substance or a shelf life for the drug product and 
recommended storage conditions. 
Q1B: Stability testing: photostability testing of new 
drug substances and products: 
The ICH Harmonized Tripartite Guideline covering the 
Stability Testing of New Drug Substances and Products 
(hereafter referred to as the Parent Guideline) notes that 
light testing should be an integral part of stress testing. 
This document is an annex to the Parent Guideline and 
addresses the recommendations for photo stability 
testing. 
Q1C: Stability Testing For New Dosage Forms 
New dosage form: A pharmaceutical product, 
containing the same active substance as included in the 
existing approved drug product, differing in: 
 Route of administration (e.g., oral to parenteral) 
 New functionality/delivery systems (e.g., 
immediate release to modified release tablet) 
 Dosage forms / same administration route (e.g., 
capsule to tablet, solution to suspension) A 
reduced stability database at submission time (e.g., 
6 months accelerated and 6 months long term data 
from on-going studies) may be acceptable in 
certain justified case. 
Q1D: BracketingandMatrixingDesigns 
Bracketing: Design of a stability schedule whereby 
only samples on the extremes of certain design factors 
(e.g., strength, container size and/or fill) are tested at all-
time points as in a full design, assuming that the stability 
of any intermediate levels is represented by the stability 
of the extremes tested.  
Matrixing: Design of a stability schedule where testing 
is performed on a selected subset of samples for one 
time point and on another subset of samples for a 
subsequent time point.  
Get buy-in from the agency ahead of implementing a 
complex design 
Q1E: Evaluation of Stability Data 
The design and execution of formal stability studies 
should follow the principles outlined in the parent 
guideline. The purpose of a stability study is to 
establish, based on testing a minimum of three batches 
of the drug substance or product, a retest period or shelf 
life and label storage instructions applicable to all future 
batches manufactured and packaged under similar 
circumstances. The degree of variability of individual 
batches affects the confidence that a future production 
batch will remain within acceptance criteria throughout 
its retest period or shelf life. 
Q1F –For Zones III and IV (Hot & Dry or Hot & 
Humid) 
ICH Code Guideline title 
Q1A Stability testing of New Drug Substances and Products (Second Revision) 
Q1B Stability testing : Photostability testing of New Drug Substances and Products 
Q1C Stability testing of New Dosage Forms 
Q1D Bracketing and Matrixing Designs for stability testing of Drug Substances and Products 
Q1E Evaluation of stability data 
Q1F Stability data package for Registration Applications in Climatic Zones 3 and 4 
Q5C Stability testing of Biotechnological/Biological Products 
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ICH Q1 F Stability Data Package for Registration 
Applications in Climatic Zones III and IV defined  
storage conditions for stability testing in countries 
located in Climatic Zones III (hot and dry) and IV (hot 
and humid), i.e. countries not located in the ICH regions 
and not covered by ICH Q1 A (R2) Stability Testing for 
New Drug Substances and Drug Products. ICH Q1 F 
described harmonised global stability testing 
requirements in order to facilitate access to medicines by 
reducing the number of different storage conditions. In 
the course of the discussions which led to the 
development of the guideline, WHO conducted a survey 
amongst their member states to find consensus on 
30°C/65% RH as the long-term storage conditions for 
hot and humid regions. As no significant objections 
were raised in this survey, 30°C/65% RH was defined as 
the long-term storage condition for Climatic Zone III/IV 
countries in ICH Q1F. The document was adopted by 
the ICH Steering Committee in February 2003 and 
subsequently implemented in the ICH regions. 
Q7: Good Manufacturing Practice Guide for Active 
Pharmaceutical Ingredients  
This document (Guide) is intended to provide guidance 
regarding good manufacturing practice (GMP) for the 
manufacturing of active pharmaceutical ingredients 
(APIs) under an appropriate system for managing 
quality. It is also intended to help ensure that APIs meet 
the requirements for quality and purity that they purport 
or are represented to possess. In this Guide 
“manufacturing” is defined to include all operations of 
receipt of materials, production, packaging, 
repackaging, labelling, relabeling, quality control, 
release, storage and distribution of APIs and the related 
controls. In this Guide the term “should” indicates 
recommendations that are expected to apply unless 
shown to be inapplicable or replaced by an alternative 
demonstrated to provide at least an equivalent level of 
quality assurance. For the purposes of this Guide, the 
terms “current good manufacturing practices” and “good 
manufacturing practices” are equivalent. The Guide as a 
whole does not cover safety aspects for the personnel 
engaged in the manufacture, nor aspects of protection of 
the environment. These controls are inherent 
responsibilities of the manufacturer and are governed by 
national laws. This Guide is not intended to define 
registration/filing requirements or modify 
pharmacopoeial requirements.  
CLIMATIC ZONE FOR STABILITY TESTING 
For the purpose of stability testing, the whole world has 
been divided into four zones (I - IV) depending upon the 
environmental conditions the pharmaceutical products 
are likely to be subjected to during their storage. These 
conditions have been derived on the basis of the mean 
annual temperature and relative humidity data in these 
regions. Based upon this data, long-term or real-time 
stability testing conditions and accelerated stability 
testing conditions have been derived. 
  
Table 2:  ICH Climatic zones and long term stability conditions 
Climatic 
Zone 
Climate/Definition Major Countries/Region MAT*/Mean annual partial 
water vapour pressure 
Long-term testing 
conditions 
I Temperate UK, Northern Europe 
Russia, United states 
<15°C/<11hPa 21°C/45%RH 
II Subtropical and 
Mediterranean 
Japan, Southern 
Europe 
>15-22°C/ >11-18 hPa 25°C/60%RH 
III Hot and Dry Iraq, India >22°C/<15 hPa>22°C/>15-27 30°C/35%RH 
IVa Hot and humid Iran, Egypt hPa 30°C/65%RH 
IVb Hot and very 
Humid 
Brazil, Singapore >22°C/>27 hPa 30°C/75%RH 
*MAT - Mean annual temperature measured in open air.2, 8, 9, 10  
 
PROTOCOL FOR STABILITY TESTING 
The protocol for stability testing is a pre-requisite for 
starting stability testing and is necessarily a written 
document that describes the key components of a 
regulated and well-controlled stability study. Because 
the testing condition is based on inherent stability of the 
compound, the type of dosage form and the proposed 
container-closure system, the protocol depends on the 
type of drug substance or the product. In addition, the 
protocol can depend on whether the drug is new or is 
already in the market
11
.  
Batches: 
Stability studies at developmental stages are generally 
carried out on a single batch while studies intended for 
registration of new product or unstable established 
product are done on first three production batches, while 
for stable and well-established batches, even two are 
allowed. If the initial data is not on a full scale 
production batch, first three batches of drug product 
manufactured post-approval should be placed on long-
term studies using the same protocol as in approved drug 
application. Data on laboratory scale batches obtained 
during development of pharmaceuticals are not accepted 
as primary stability data but constitute supportive 
information. In general, the selection of batches should 
constitute a random sample from the population of pilot 
or production batches
1
.  
Containers and closures: 
The testing is done on the product in immediate 
containers and closures proposed for marketing. The 
packaging materials include aluminium strip packs, 
blister packs, HDPE bottles etc. This may also include 
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secondary packs, but not shippers. Products in all 
different types’ of containers/closures, whether meant 
for distribution or for physician and promotional 
samples, are to be tested separately. However, for bulk 
containers, testing in prototype containers is allowed, if 
it simulates the actualpackaging
1, 2
.  
Sampling time points: 
Frequency of testing should be such that it is sufficient 
to establish the stability profile of the new drug 
substance. For products with a proposed shelf life of at 
least 12 months, the testing frequency at the long-term 
storage condition should be every 3 months over the first 
year, every 6 months over the second year and annually 
thereafter throughout the proposed shelf life expiration 
date. In the case of accelerated storage conditions, a 
minimum of three time points, including the initial and 
end points, for example, 0, 3, and 6 months is 
recommended. When testing at the intermediate storage 
condition is necessary as a result of significant change at 
the accelerated storage condition, a minimum of four test 
points, including the initial and final time points, is 
recommended, for example, 0, 6, 9 and 12 months
12
. 
 
Table 3:  Test Schedule for stability testing of new products
1, 2
 
Environment Sampling Time 
Points (months) 
Method & Climatic zone 
25°C/60% RH 3, 6, 9, 12, 18, 24,36 Long term for zones I and IV 
30°C/35% RH 3, 6, 9, 12, 18, 24,36 Long term for zones III 
30°C/65% RH 3, 6, 9, 12, 18, 24,36 Long term for zone IVa, or intermediate condition for zones I and II 
30°C/75% RH 3, 6, 9, 12, 18, 24,36 Long term for zone IVa, or intermediate condition for zones I and II 
40°C/75% RH 3, 6, 9, 12, 18, 24,36 Accelerated condition for all zones 
 
Test storage conditions:  
The storage conditions to be selected are based upon the 
climatic zone in which the product is intended to be 
marketed or for which the product is proposed to be filed 
for regulatory approval. General recommendations on 
the storage conditions have been given by ICH, CPMP 
and WHO. 
 
Table 4: Stability test storage conditions for drug products
7, 9, 12
. 
Intended storage 
condition 
Stability Test 
Method 
ICH Test temperature and 
humidity (Period in months) 
WHO Test temperature and 
humidity (Period in months) 
Room 
Temperature 
Long term 25±2°C/60±5% RH(12) 25±2°C/60±5%RH or 
30±2°C/65±5%RH 
30±2°C/75±5% RH (12) 
Refrigerated Long term 5°C/ambient (12) 5±3°C 
Freezer Long term -20°C/ambient (12) -20°C±5°C 
 
Estimation of shelf life:  
The shelf life is determined from the data obtained from 
the long term storage studies. The data is first linearized 
and test for goodness of fit is applied. The linearized 
data is then analyzed to see that the slope and the 
intercepts are matching. Table 7 gives the different 
possibilities in the pattern of the concentration-time data 
of the three batches. The data is pooled accordingly and 
used for estimation of the common slope
2
. 
Recent trends in stability testing  
Current trend, especially amongst the multinational 
pharmaceutical companies, is to define conditions for 
stability testing for global marketing. For this the 
companies are orienting their protocols to single set of 
conditions that covers extreme environmental 
conditions. The specific changes for global testing 
include increase in duration of accelerated testing period 
from 6 to 12 months, and conduct of additional tests at 
50°C/75% RH for 3 months
13
. The concept behind this 
change is to avoid repetition of stability testing for other 
regions and efficient and optimum use of resources as all 
tests are done in one laboratory. Moreover testing under 
combination of three environmental factors, viz., 
temperature, humidity and light, has been reported to 
result in stronger deleterious effect on drug substances 
and products, than under temperature and humidity 
conditions only
1, 2, 14, 15, 16
. 
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